Early Access Program for ALXN1840 in Patients with Wilson Disease
Study identifier:D9430R00001
ClinicalTrials.gov identifier:NCT05686564
EudraCT identifier:N/A
CTIS identifier:N/A
Other
Official Title
Early Access Program for ALXN1840 in Patients with Wilson Disease
Medical condition
Wilson Disease
Phase
-
Healthy volunteers
-
Study drug
ALXN1840
Sex
All
Actual Enrollment
-
Study type
Expanded Access
Age
3 Years +
Date
Study Start Date: -
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 May 2023 by Alexion Pharmaceuticals, Inc.
Sponsors
Alexion Pharmaceuticals, Inc.
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
